4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:DNA表达载体
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > vector > 牛津遗传学/pSF MinCMV Puro(OG579)最小CMV嘌呤霉素载体/OG579/1 Ea
商品详细牛津遗传学/pSF MinCMV Puro(OG579)最小CMV嘌呤霉素载体/OG579/1 Ea
牛津遗传学/pSF MinCMV Puro(OG579)最小CMV嘌呤霉素载体/OG579/1 Ea
牛津遗传学/pSF MinCMV Puro(OG579)最小CMV嘌呤霉素载体/OG579/1 Ea
商品编号: OG579
品牌: oxgene
市场价: ¥5033.80
美元价: 3020.28
产地: 美国(厂家直采)
公司:
产品分类: 载体
公司分类: vector
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Plasmid Info:

Plasmid Information

Product Name: pSF-MinCMV-Puro

Product Code: OG579

Size (bp): 4330 bp

Bacterial Antibiotic Selection: KanR

Origin and Compatibility: pUC high copy derived from pBR322

Bacterial Copy Number: 500-700 per cell

Promoter: Minimal CMV (Cytomegalovirus) promoter

Plasmid Purpose:

In this plasmid the minimal CMV promoter regulates expression of the puromycin resistance gene providing basal levels of expression in most mammalian cells. An upstream MCS enables additional regulatory elements to be introduced upstream of the minimal promoter to make it responsive to cell-associated transcription factors (either stimulatory or repressive) or externally-applied drugs. In this way a range of sophisticated vectors can be prepared that provide puromycin resistance under carefully-defined conditions.

Promoter Expression Level:

This plasmid contains the minimal CMV immediate early promoter with a multiple cloning site immediately upstream that allows transcription factor binding sites to be inserted. This allows tissue specific or physiologically responsive promoters to be created.

Sequence and Map:

Other Info:

Transcription Termination:

This plasmid contains three alternative transcription terminators for mammalian bacterial and bacteriophage (T7) expression. This means that only the promoter needs to be changed to alter the expression system you are using. We sell multiple promoters that can be used in each of these systems. The presence of each terminator does not reduce expression in the alternative systems.

Cloning:

Cloning in a gene:

This plasmid contains a gene within the main multiple cloning site (NotI-ClaI). Any plasmid that we sell where the gene is this configuration will be located in the exact same position in relation to the start and stop codon of the gene. The only exceptions to this rule are fusions proteins where the fusion gene may be positioned at the front or end of the MCS to allow gene fusion.

By positioning all of our genes in the same location it allows them to be transferred between plasmids using the same cloning method and restriction sites regardless of the plasmid being used from our product range. Inserting a new gene into this plasmid should be easily possible using a range of standard restriction enzyme sites that flank the gene currently in the vector.

Multiple cloning site notes:

In the multiple cloning site there are two important restriction sites called BsgI and BseRI sites. These sites both cut the DNA at the same position and cleave the stop codon of the gene in the multiple cloning site in this plasmid thereby producing a TA overhang. This overhang is compatible with any of our peptide or reporter fusion tag plasmids also cut with either of these enzymes. This allows seamless C-terminal fusions to be made with the gene in this multiple cloning site using a single cloning step from our C-terminal peptide and reporter tag product range. Normally the easiest method is to clone the C-terminal tag from our other plasmid products into this plasmid using BsgI or BseRI and the downstream ClaI restriction site.

BseRI and BsgI sites are non-palindromic and cleave a defined number of bases away from their binding sites. This allows them to cut the upstream stop codon in the gene in this plasmid regardless of the gene sequence.

IP Status:

Intellectual Property Status

This product is part of our SnapFast plasmid range, for more information on the Intellectual property status of this plasmid please click here

品牌介绍
OXGENE的技术平台和专家解决方案加速了细胞和基因疗法的发现,开发和制造。我们解决了现代生物学中基因治疗,抗体治疗和基因编辑方面最重要和最具挑战性的问题。我们的技术可以实现精确而强大的哺乳动物细胞工程。我们以自动化和信息学为导向的方法意味着我们解决了其他人无法推进新疗法交付的问题。